UK-based Allergy Therapeutics announced that the U.S. Food & Drug Administration had cleared the Group’s Investigational New Drug application for its novel virus-like particle (VLP)-based peanut allergy vaccine candidate.
The clearance by the FDA of the Group’s IND application paves the way for the initiation of the Phase I PROTECT trial, which will run in the U.S.
The trial will include multiple cohorts beginning with healthy subjects, followed by peanut-allergic patients who will undergo skin prick tests, and then peanut-allergic patients who will receive subcutaneous injections.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.